MSN: Why Artificial Intelligence Could Help Save the Planet
In an MSN interview, AI executive Emil Eifrem argues that responsible use of artificial intelligence can enhance sustainability, optimize supply chains, and address environmental challenges, exemplified by Dotmatics' application of AI to accelerate drug discovery and improve R&D efficiency while reducing resource use.
In a recent interview with MSN, AI executive Emil Eifrem challenges the prevailing narrative that artificial intelligence is a threat to humanity or the environment. Instead, he argues that, when applied responsibly, AI has the potential to accelerate sustainability efforts, optimize supply chains, and solve some of the world’s most pressing environmental challenges.
The article also spotlights Dotmatics as a real-world example of AI being used for good. By applying artificial intelligence to scientific research, Dotmatics helps organizations accelerate drug discovery, reduce resource-intensive lab work, and optimize R&D workflows. Dotmatics demonstrates how AI can contribute to both scientific and environmental progress.
Related
The Future of AI in Drug Discovery
The Forbes article discusses how AI is revolutionizing drug discovery by accelerating R&D and improving decision-making, highlighting Dotmatics’ role in integrating data and applying AI to scientific workflows, while also connecting these advancements to broader innovations in sustainability and global problem-solving.
Techstrong TV: AI Leadership Insights for Scientific Research and Drug Discovery
In this Techstrong TV interview, Dotmatics CEO Thomas Swalla discusses how the company leverages AI to accelerate scientific research and drug discovery by streamlining workflows, enabling breakthroughs, and reducing costs in R&D.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
Lab Manager: AI in the Lab for Faster, Smarter Drug Discovery
Dotmatics VP of Strategy Christian Olsen explains in a Lab Manager article how AI enhances laboratory workflows by improving data analysis and accelerating decision-making, thereby augmenting research processes and boosting efficiency and innovation in drug discovery without replacing physical experiments.
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.
NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.